Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (Redefine)

November 11, 2026 updated by: COMPASS Pathways

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • British Columbia
      • Kamloops, British Columbia, Canada, V2C 5T1
        • Recruiting
        • BC
      • North Vancouver, British Columbia, Canada, V7P2T4
        • Recruiting
        • BC
      • Penticton, British Columbia, Canada, V2A5L5
        • Recruiting
        • BC
    • Arizona
      • Tucson, Arizona, United States, 85704
        • Recruiting
        • AZ
    • California
      • Irvine, California, United States, 92612
        • Recruiting
        • CA
      • Los Angeles, California, United States, 90025
        • Recruiting
        • CA
      • Moorpark, California, United States, 93021
        • Recruiting
        • CA
      • San Jose, California, United States, 95124
        • Recruiting
        • CA
    • Florida
      • Miami, Florida, United States, 33125
        • Recruiting
        • FL
      • Orlando, Florida, United States, 32801
        • Recruiting
        • FL
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • IL
    • Massachusetts
      • Boston, Massachusetts, United States, 02116
        • Recruiting
        • MA
    • Minnesota
      • Eden Prairie, Minnesota, United States, 55347
        • Recruiting
        • MN
    • Nebraska
      • Lincoln, Nebraska, United States, 68526
        • Recruiting
        • NE
    • Nevada
      • Las Vegas, Nevada, United States, 89119
        • Recruiting
        • NV
    • New York
      • New York, New York, United States, 10025
        • Recruiting
        • NY
      • The Bronx, New York, United States, 10461
        • Recruiting
        • NY
    • Ohio
      • North Canton, Ohio, United States, 44720
        • Recruiting
        • OH
    • Texas
      • Carrollton, Texas, United States, 75010
        • Recruiting
        • TX
    • Utah
      • Orem, Utah, United States, 84058
        • Recruiting
        • UT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years or older
  • Diagnosed with PTSD at least 6 months ago

Exclusion Criteria:

- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1 mg COMP360 psilocybin

COMP360 psilocybin administered with monitoring and support

Experimental: 10 mg COMP360 psilocybin

COMP360 psilocybin administered with monitoring and support

Experimental: 25 mg COMP360 psilocybin

COMP360 psilocybin administered with monitoring and support

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity score
Time Frame: 8 weeks

The CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) is a 30-item structured interview that yields a total severity score (0-80) reflecting PTSD symptoms. A higher CAPS-5 score indicates more severe, intense, and frequent PTSD symptoms.

8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 14, 2026

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

April 30, 2026

First Submitted That Met QC Criteria

April 30, 2026

First Posted (Actual)

May 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • COMP202

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.